Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: \- Signed, informed consent * Ability and willingness to comply with the requirements of the study protocol * Age ≥18 years * Diagnosis of the following histories according to the WHO criteria 1. CLL or SLL 2. MCL * For patients with SLL, peripheral blood flow cytometry must be positive with CLL-like cells accounting for at least 1% of circulating WBC. * No prior systemic therapy for disease under study except: 1. prior local radiation for symptomatic disease is permitted 2. Short course systemic corticosteroids is permissible for disease control, improvement of…